Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DTIL

Precision Biosciences Inc

May 13 • 04:00PM ET

11.50

Dollar change +0.86
Percentage change 8.08	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-18.25	Insider Own	11.92%	Shs Outstand	4.16M	Perf Week	7.88%
Market Cap	46.69M	Forward P/E	-	EPS next Y	-5.62	Insider Trans	-31.57%	Shs Float	3.58M	Perf Month	-18.56%
Income	-69.77M	PEG	-	EPS next Q	-2.10	Inst Own	67.89%	Short Float	9.38%	Perf Quarter	2.19%
Sales	48.73M	P/S	0.96	EPS this Y	44.67%	Inst Trans	-66.79%	Short Ratio	2.56	Perf Half Y	-2.71%
Book/sh	4.53	P/B	2.54	EPS next Y	36.41%	ROA	-31.41%	Short Interest	0.34M	Perf Year	-48.89%
Cash/sh	28.74	P/C	0.40	EPS next 5Y	-	ROE	-157.63%	52W Range	8.25 - 27.02	Perf YTD	5.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	7.97%	ROI	-262.43%	52W High	-57.44%	Beta	1.69
Dividend TTM	-	Quick Ratio	2.73	Sales past 5Y	101.03%	Gross Margin	83.06%	52W Low	39.39%	ATR (14)	0.90
Dividend Ex-Date	-	Current Ratio	2.73	EPS Y/Y TTM	56.27%	Oper. Margin	-130.74%	RSI (14)	52.01	Volatility	7.52% 7.80%
Employees	109	Debt/Eq	1.66	Sales Y/Y TTM	94.15%	Profit Margin	-143.18%	Recom	1.33	Target Price	33.00
Option/Short	No / Yes	LT Debt/Eq	0.41	EPS Q/Q	47.27%	Payout	-	Rel Volume	0.80	Prev Close	10.64
Sales Surprise	229.33%	EPS Surprise	171.76%	Sales Q/Q	-33.59%	Earnings	May 13 BMO	Avg Volume	131.44K	Price	11.50
SMA20	8.04%	SMA50	-4.03%	SMA200	-5.58%	Trades		Volume	105,701	Change	8.08%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Guggenheim	Buy	$19
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$7
Jun-09-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-27-20	Resumed	BTIG Research	Buy	$16
Apr-03-20	Downgrade	Goldman	Buy → Neutral	$24 → $7
Mar-05-20	Initiated	Stifel	Buy	$21
Feb-25-20	Initiated	William Blair	Outperform
Aug-09-19	Initiated	BTIG Research	Buy	$22
Jul-16-19	Initiated	H.C. Wainwright	Buy	$21
Apr-22-19	Initiated	JP Morgan	Overweight
Apr-22-19	Initiated	Jefferies	Buy
Apr-22-19	Initiated	Goldman	Buy
Apr-22-19	Initiated	Barclays	Overweight

Show Previous Ratings

Today 11:53AM	DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +8.08%
07:22AM	Precision BioSciences Reports Profit From Cont. Ops. In Q1 (RTT News)
07:08AM	Precision BioSciences: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-08-24 08:15AM	Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement (Business Wire) +6.62%
04:30PM	Loading…
May-07-24 04:30PM	Precision BioSciences to Report First Quarter Results on May 13, 2024 (Business Wire)
08:30AM	Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECUREs Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency (Business Wire)
May-03-24 09:33AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-01-24 07:05AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 (Business Wire)
Apr-16-24 04:15PM	Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics (Business Wire)
Apr-11-24 09:55AM	Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Apr-02-24 09:55AM	Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know (Zacks) -7.61%
06:48AM	Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-27-24 11:53AM	DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:10AM	Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:07AM	Loading…
07:07AM	Precision BioSciences: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update (Business Wire)
Mar-20-24 04:30PM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 (Business Wire)
Mar-19-24 07:00AM	Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy (Business Wire)
Mar-14-24 08:15AM	MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.70%
Mar-06-24 08:45AM	Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency (Business Wire)
Mar-01-24 06:30AM	Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants (Business Wire) -31.24%
Feb-29-24 04:01PM	Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants (Business Wire)
09:22AM	TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 04:25AM	Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength? (Zacks)
Feb-20-24 07:00AM	Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences (Business Wire) +9.28%
Feb-14-24 07:00AM	Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness (Business Wire) +7.32%
Feb-13-24 07:00AM	Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations (Business Wire)
Feb-12-24 07:00AM	Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases (Business Wire)
Feb-09-24 07:00AM	Precision BioSciences to Effect a Reverse Stock Split (Business Wire)
07:00AM	Loading…
Jan-09-24 07:00AM	TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precisions Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases (GlobeNewswire) +10.10%
07:00AM	Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases (Business Wire)
Dec-13-23 08:20AM	Precision BioSciences Announces Approval of First Clinical Trial Application of ARCUS Gene Insertion Program by Partner iECURE (Business Wire)
Dec-04-23 07:00AM	Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases (Business Wire) +5.81%
Nov-30-23 07:00AM	Precision BioSciences to Present at Hep-DART 2023 (Business Wire)
Nov-28-23 07:00AM	Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.53%
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-13-23 07:05AM	Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLDs The Liver Meeting 2023 (Business Wire) -9.45%
Nov-10-23 07:00AM	Precision BioSciences to Present at Upcoming Sidoti Conference (Business Wire)
Nov-09-23 07:00AM	Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (Business Wire)
Nov-07-23 07:54AM	Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results (GuruFocus.com)
07:17AM	Precision BioSciences: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-01-23 07:00AM	Precision BioSciences to Report Third Quarter Results on November 7, 2023 (Business Wire) +29.63%
Oct-26-23 07:30AM	Precision BioSciences Presents Preclinical Data Highlighting Capabilities of ARCUS for Gene Insertion and Excision at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (Business Wire)
Oct-23-23 07:00AM	Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference (Business Wire)
Oct-12-23 08:00AM	Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress (Business Wire)
Sep-27-23 07:00AM	Precision BioSciences Receives U.S. Patent Allowance Covering PBGENE-PMM for m.3243-Associated Mitochondrial Diseases (Business Wire)
Sep-12-23 07:00AM	Precision BioSciences Hosts Virtual R&D Day Highlighting its Proprietary ARCUS Technology and Recent In Vivo Gene Editing Program Developments (Business Wire)
Sep-06-23 07:00AM	Precision BioSciences to Attend and Present at Upcoming September Investor Conferences (Business Wire) -6.43%
Aug-31-23 07:00AM	Precision BioSciences to Host In Vivo Gene Editing R&D Day on September 12, 2023 (Business Wire) -5.92%
Aug-22-23 07:32AM	Why Durham biotech's strategy shift means smaller, leaner company (American City Business Journals)
07:32AM	Why Durham biotech's pivot means smaller, leaner company (American City Business Journals)
Aug-18-23 09:35AM	After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL) (Zacks)
Aug-15-23 07:04PM	Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer (Business Wire)
Aug-06-23 08:03AM	Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL) (Simply Wall St.)
Aug-04-23 08:35AM	Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:23AM	Precision BioSciences: Q2 Earnings Snapshot (AP Finance)
07:15AM	Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-01-23 05:00PM	Precision BioSciences to Report Second Quarter Results on August 4, 2023 (Business Wire)
Jul-27-23 07:30AM	Precision BioSciences Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of In Vivo R&D Day (Business Wire)
Jul-13-23 01:03PM	3 Penny Stocks to Catapult You Into the Millionaires Club (InvestorPlace)
Jun-22-23 07:00AM	Precision BioSciences Announces Oral Presentation of Positive ARCUS® Gene Editing Data at International Liver Congress 2023 (Business Wire)
Jun-05-23 07:00AM	Precision BioSciences to Present at Upcoming June Investor Conferences (Business Wire) +8.00%
May-31-23 07:15AM	Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward (Business Wire) -11.90%
May-25-23 07:00AM	Precision BioSciences to Provide an Update on its Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on May 31, 2023 (Business Wire) -10.17%
May-24-23 08:00AM	Precision BioSciences to Participate in Upcoming Stifel Genetic Medicines Day (Business Wire) -5.47%
May-19-23 07:00AM	Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting (Business Wire) +6.41%
May-12-23 05:06PM	Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting (Business Wire)
May-09-23 08:15AM	Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:21AM	Precision BioSciences: Q1 Earnings Snapshot (AP Finance)
07:00AM	Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-08-23 04:30PM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-02-23 07:00AM	Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023 (Business Wire)
Apr-20-23 08:00AM	Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023 (Business Wire)
Apr-19-23 04:22PM	Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting (Business Wire)
Apr-17-23 07:34AM	Little Excitement Around Precision BioSciences, Inc.'s (NASDAQ:DTIL) Revenues (Simply Wall St.)
Apr-13-23 07:00AM	Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease (Business Wire) +10.99%
Mar-27-23 07:00AM	Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference (Business Wire) +5.70%
Mar-09-23 08:15AM	Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -11.30%
07:00AM	Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-07-23 06:33AM	A Precision BioSciences, Inc. (NASDAQ:DTIL) insider increased their holdings by 38% last year (Simply Wall St.)
Mar-02-23 07:00AM	Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023 (Business Wire)
Feb-24-23 07:00AM	Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes (Business Wire)
Feb-22-23 07:00AM	Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference (Business Wire)
Feb-14-23 07:00AM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-20-23 08:13AM	Shareholders in Precision BioSciences (NASDAQ:DTIL) have lost 88%, as stock drops 11% this past week (Simply Wall St.)
Jan-09-23 07:30AM	Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones (Business Wire) -8.09%
Jan-06-23 07:00AM	Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Companys Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate (Business Wire)
Dec-10-22 10:00AM	Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting (Business Wire)
Nov-11-22 10:04AM	Precision BioSciences Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.) +6.52%
Nov-10-22 05:00PM	Precision BioSciences Announces Change to its Board of Directors (Business Wire)
Nov-08-22 08:25AM	Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-04-22 07:19PM	Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.14%
Nov-03-22 09:40AM	Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-02-22 07:00AM	Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022 (Business Wire)
Oct-26-22 07:00AM	Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-25-22 06:40AM	Precision BioSciences, Inc. (NASDAQ:DTIL) is definitely on the radar of institutional investors who own 49% of the company (Simply Wall St.)
Oct-11-22 03:00AM	Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress (Business Wire)

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Amoroso Michael	President and CEO	May 02 '24	Sale	10.32	1,526	15,748	13,772	May 03 06:29 PM
List Alan	Chief Medical Officer	May 02 '24	Sale	10.32	290	2,993	4,488	May 03 06:30 PM
Scimeca Dario	General Counsel and Secretary	May 02 '24	Sale	10.32	272	2,807	5,680	May 03 06:33 PM
SMITH J. JEFFERSON	Chief Research Officer	May 02 '24	Sale	10.32	154	1,589	67,613	May 03 06:32 PM
List Alan	Chief Medical Officer	Apr 30 '24	Sale	10.03	238	2,386	3,796	Apr 30 06:34 PM
SMITH J. JEFFERSON	Chief Research Officer	Jan 23 '24	Sale	0.37	28,000	10,360	1,987,269	Jan 23 07:11 PM
Amoroso Michael	President and CEO	Jan 22 '24	Sale	0.36	137,390	49,460	356,433	Jan 23 07:17 PM
List Alan	Chief Medical Officer	Jan 22 '24	Sale	0.36	21,526	7,749	94,982	Jan 23 07:13 PM
Scimeca Dario	General Counsel and Secretary	Jan 22 '24	Sale	0.36	21,287	7,663	151,028	Jan 23 07:15 PM
Amoroso Michael	President and CEO	Nov 03 '23	Sale	0.40	125,025	50,010	227,103	Nov 06 05:07 PM
Scimeca Dario	General Counsel and Secretary	Nov 03 '23	Sale	0.40	16,023	6,409	112,970	Nov 06 05:09 PM
Scimeca Dario	General Counsel and Secretary	Jun 08 '23	Sale	0.75	13,361	10,021	68,473	Jun 09 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DTIL

Precision Biosciences Inc

Upgrade your FINVIZ experience